<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692562</url>
  </required_header>
  <id_info>
    <org_study_id>SIK2005</org_study_id>
    <nct_id>NCT00692562</nct_id>
  </id_info>
  <brief_title>Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease</brief_title>
  <official_title>Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuzhou General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuzhou General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the efficiency and safety of simultaneous islet-kidney
      transplantation in patients of type 1 diabetes with end-stage renal disease using a
      glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. Islet
      transplantation can result in insulin independence with excellent metabolic control when
      glucocorticoid-free immunosuppression is combined with the infusion of an adequate islet
      mass. Alemtuzumab (Campath-1H ®) is a 150-kDa humanized IgG1 monoclonal antibody that targets
      the CD52 antigen. Prolonged lymphocyte depletion can be expected following alemtuzumab
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exogenous insulin requirement</measure>
    <time_frame>5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>kidney function</measure>
    <time_frame>5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose and C-peptide levels</measure>
    <time_frame>5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portal vein Ultrasound</measure>
    <time_frame>1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function</measure>
    <time_frame>5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Blood Count</measure>
    <time_frame>5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>autoantibodies</measure>
    <time_frame>5</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>simultaneous islet-kidney transplantation</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients age 18 to 60 years of age.

          -  Ability to provide written informed consent.

          -  Clinical history compatible with type 1 diabetes (T1DM) as defined by the WHO
             guidelines(1999) on the Diagnosis and classification of Diabetes Mellitus.

          -  manifest signs and symptoms that are severe enough to be incapacitating.

          -  Basal C-peptide&lt;0.5ng/mL

          -  patients with poor diabetes control (HbA1c &gt;7% but &lt;12%)

          -  progressive diabetic complications.

          -  end-stage renal disease(serum creatinine&gt;450μmol/l)

        Exclusion Criteria:

          -  age &lt;18 years or &gt;60 years

          -  diabetic history &lt;5 years

          -  BMI&gt;27

          -  body weight &gt;80kg

          -  exogenous insulin requirement &gt;1 unit/kg/day

          -  severe anemia (male &lt;8g/dl, female &lt;7g/dl)

          -  low white blood cell count (&lt;3000/dl)

          -  liver dysfunction

          -  Symptomatic peptic ulcer disease

          -  Any malignancy

          -  Active infection including hepatitis B, hepatitis C, HIV, or TB

          -  panel reactive antibody &gt;20%

          -  Any medical condition that, in the opinion of the investigator, will interfere with
             the safe completion of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianming Tan, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuzhou General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuzhou General Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>September 15, 2011</last_update_submitted>
  <last_update_submitted_qc>September 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>FUZHOU GENERAL HOSPITAL</name_title>
    <organization>FUZHOU GENERAL HOSPITAL</organization>
  </responsible_party>
  <keyword>Islets of Langerhans Transplantation</keyword>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>alemtuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

